FDA Panel Votes Against Novo Nordisk's Weekly Insulin for Type 1 Diabetes Patients
Saturday, 25 May 2024, 01:47
FDA Panel Votes Against Novo Nordisk's Weekly Insulin for Type 1 Diabetes Patients
In a recent decision, U.S. health regulators advised against the use of Novo Nordisk's weekly insulin in patients with type 1 diabetes. The panel raised concerns over the risks associated with low blood sugar, highlighting potential safety issues.
This rejection could have a substantial impact on Novo Nordisk's market position and future innovations in diabetes treatment.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.